NCT05625971 2026-01-07
NIRVANA
Columbia University
Completed
Clinical Trials
12 trialsNCT07045168 2025-09-15
Risk-adapted Therapeutic Strategy in +1q NDMM
The First Hospital of Jilin University
Not yet recruiting
NCT05203003 2024-12-06
MRD-CONFIRM
Assistance Publique - Hôpitaux de Paris
Recruiting
NCT04545333 2024-08-01
The clonoSEQ® Watch Registry
Adaptive Biotechnologies
Terminated
NCT06109233 2024-07-05
MRD
The First Hospital of Jilin University
Recruiting
NCT06463717 2024-06-24
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
First Affiliated Hospital of Zhejiang University
Recruiting
NCT06302699 2024-03-12
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Recruiting
NCT05578625 2022-10-13
ctDNA Methylation Sequencing for Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Unknown
NCT05536700 2022-09-13
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Unknown
NCT02627261 2022-09-06
MMRD
Hospices Civils de Lyon
Completed
NCT03702088 2019-11-19
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
University Hospital, Montpellier
Unknown
NCT04122092 2019-11-18
EUCADD
Shanghai Changzheng Hospital
Unknown